Elkanah Omenge Orang’o
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elkanah Omenge Orang’o has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Peter Itsura
Eldoret Teaching and Referral Hospital, Eldoret, Kenya
6 shared publicationsBarry Rosen
Department of Gynecologic Oncologist, Oakland University William Beaumont, Rochester Hills, MI, USA
5 shared publicationsHellen Muliro
Ampath Oncology Institute
4 shared publicationsKapten Muthoka
Academic Model Providing Access to Healthcare Partnership , Eldoret , Kenya
4 shared publicationsPhilip Tonui
AMPATH Oncology, Eldoret, Kenya
4 shared publicationsAaron Ermel
Indiana University School of Medicine, Indianapolis, IN
3 shared publications
Latest Publications
- Open Access
- 27 November 2024
- Published by Springer Nature in Research Square
Early Clinical Outcomes and Associated Clinical Characteristics of Infertile Women on in-vitro Fertilization Treatment at a Tertiary Private Hospital in Kenya
Conclusions: Majority of the women who sought IVF treatment were married for at least five years, had a tertiary level of education, formally employed with health insurance and reproductive disorders. The overall pregnancy success rate 12 weeks after IVF treatment at Mediheal fertility centers is 37.1%. Previous fertility treatment was significantly associated with favourable early clinical outcomes of IVF, while having a normal BMI and regular menstrual cycle does not significantly increase the likelihood of normal pregnancy after IVF. Background: Infertility is a major cause of marital conflict and influences the quality of life of couples and their wellbeing. One of the definitive treatments for infertility is in-vitro fertilization (IVF). Despite this, not all patients who receive IVF treatment have favourable desirable clinical outcomes due to multiple underlying patients and procedural characteristics. Objectives: To determine early clinical characteristics and outcomes among women undergoing in-vitro fertilization treatment at a private tertiary hospital and fertility centers in Kenya. Methods: This was a one-year observational prospective study involving 153 women undergoing invitro fertilization as definitive treatment for infertility at Mediheal fertility centers in Eldoret and Nairobi. The participants were sampled consecutively over a nine-month accrual period and followed up at 2, 6 and 12 weeks of IVF treatment. Sociodemographic characteristics were collected using interviewer administered questionnaire. Pregnancy tests, first and second obstetric ultrasound were done on the 2nd, 6th and 12th week after IVF treatment in order to determine early clinical outcomes. Pearson chi-square test and independent samples t-test were used to compare Clinical and Sociodemographic Characteristics and early clinical outcomes. Logistic regression model was used to assess the determinants of IVF success (critical value ≤0.05). Results: The mean age of participants was 36.2 (± 5.7) years. Majority 140 (91.5%) were married, 132 (86.3%) had a tertiary level education, 109 (71.2%) had health insurance and 95 (62.1%) had tried to have children for at least five years. Primary infertility was diagnosed among 83 (54.2%) women, 120 (78.4%) had regular menstrual cycle, regular coitus (>4 times a month) was in % 71 (46.4%) and 112 (73.2%) women had reproductive disorders. Pregnancy tests done on the second and eighth week among 145 women, had a positivity rate of 51.7% (n=75). On the week 6 visit, 61 of 70 women who had an obstetric ultrasound had a normal pregnancy. At 12th week visit, all the 61 women returned for an obstetric ultrasound, with 52 being normal. The overall pregnancy success rates at weeks 2, 6 and 12 were 51.7%, 43.6% and 37.1% respectively. Women with a regular menstrual cycle (AOR=1.089; 95% CI: 0.741, 1.599) and primary infertility (AOR=1.051; 0.748, 1.477) were more likely to have positive pregnancy tests on the first follow-up visits. A normal BMI (AOR=2.216; 0.663, 7.405) and regular menstrual cycle (AOR=1.406; 0.398, 4.973) increased the likelihood of normal pregnancy at 12 weeks after IVF treatment. Previous intrauterine insemination (IUI) was significantly associated with normal pregnancy outcome after 12 weeks of IVF treatment.
- 27 November 2024
- Published by Springer Nature in Research Square
Open AccessEarly Clinical Outcomes and Associated Clinical Characteristics of Infertile Women on in-vitro Fertilization Treatment at a Tertiary Private Hospital in Kenya
Conclusions: Majority of the women who sought IVF treatment were married for at least five years, had a tertiary level of education, formally employed with health insurance and reproductive disorders. The overall pregnancy success rate 12 weeks after IVF treatment at Mediheal fertility centers is 37.1%. Previous fertility treatment was significantly associated with favourable early clinical outcomes of IVF, while having a normal BMI and regular menstrual cycle does not significantly increase the likelihood of normal pregnancy after IVF. Background: Infertility is a major cause of marital conflict and influences the quality of life of couples and their wellbeing. One of the definitive treatments for infertility is in-vitro fertilization (IVF). Despite this, not all patients who receive IVF treatment have favourable desirable clinical outcomes due to multiple underlying patients and procedural characteristics. Objectives: To determine early clinical characteristics and outcomes among women undergoing in-vitro fertilization treatment at a private tertiary hospital and fertility centers in Kenya. Methods: This was a one-year observational prospective study involving 153 women undergoing invitro fertilization as definitive treatment for infertility at Mediheal fertility centers in Eldoret and Nairobi. The participants were sampled consecutively over a nine-month accrual period and followed up at 2, 6 and 12 weeks of IVF treatment. Sociodemographic characteristics were collected using interviewer administered questionnaire. Pregnancy tests, first and second obstetric ultrasound were done on the 2nd, 6th and 12th week after IVF treatment in order to determine early clinical outcomes. Pearson chi-square test and independent samples t-test were used to compare Clinical and Sociodemographic Characteristics and early clinical outcomes. Logistic regression model was used to assess the determinants of IVF success (critical value ≤0.05). Results: The mean age of participants was 36.2 (± 5.7) years. Majority 140 (91.5%) were married, 132 (86.3%) had a tertiary level education, 109 (71.2%) had health insurance and 95 (62.1%) had tried to have children for at least five years. Primary infertility was diagnosed among 83 (54.2%) women, 120 (78.4%) had regular menstrual cycle, regular coitus (>4 times a month) was in % 71 (46.4%) and 112 (73.2%) women had reproductive disorders. Pregnancy tests done on the second and eighth week among 145 women, had a positivity rate of 51.7% (n=75). On the week 6 visit, 61 of 70 women who had an obstetric ultrasound had a normal pregnancy. At 12th week visit, all the 61 women returned for an obstetric ultrasound, with 52 being normal. The overall pregnancy success rates at weeks 2, 6 and 12 were 51.7%, 43.6% and 37.1% respectively. Women with a regular menstrual cycle (AOR=1.089; 95% CI: 0.741, 1.599) and primary infertility (AOR=1.051; 0.748, 1.477) were more likely to have positive pregnancy tests on the first follow-up visits. A normal BMI (AOR=2.216; 0.663, 7.405) and regular menstrual cycle (AOR=1.406; 0.398, 4.973) increased the likelihood of normal pregnancy at 12 weeks after IVF treatment. Previous intrauterine insemination (IUI) was significantly associated with normal pregnancy outcome after 12 weeks of IVF treatment.
- Open Access
Prediction of Outcomes in Infants with Hydrops Fetalis by Mode of Delivery: A Retrospective Cohort from a Low-Resource Setting in Kenya
BACKGROUND: Hydrops fetalis is a condition associated with increased perinatal and neonatal mortality and morbidity. The overall survival rate of infants diagnosed with hydrops fetalis is currently estimated to be 27%, despite advanced intrauterine and neonatal care. Factors that contribute to poor perinatal and neonatal outcomes have been identified; however, little is known about the existing specific tool for predicting perinatal outcomes by mode of delivery. OBJECTIVE: This study aimed to determine whether cesarean section improves the perinatal outcomes of infants with hydrops fetalis in low-resource settings. STUDY DESIGN: This was a retrospective cohort study in which 102 medical records of pregnancies complicated by hydrops fetalis were retrieved. For all included women, transabdominal ultrasound was performed during pregnancy as part of the standard diagnostic modality for hydrops fetalis. The medical records of all pregnant women and their newborns were retrieved and reviewed to collect information related to the outcomes by mode of delivery, either cesarean section or vaginal delivery. The pregnant women were divided into the following 4 classes based on the severity of hydrops fetalis determined by obstetric ultrasound findings: class I (mild features of hydrops fetalis), II (moderate features of hydrops fetalis), III (moderately severe features of hydrops fetalis), and IV (severe features of hydrops fetalis). The significance of the obtained data was set at a two-tailed p<0.05. RESULTS: This cohort study estimated the proportion of hydrops fetalis to be 0.8%. Nonimmune hydrops fetalis was the common type, accounting for 75.6% of all cases. The 7-day survival rate was estimated to be 42.2%. There was no statistically significant association between the mode of delivery and perinatal survival (pv=0.84). Survival increased, especially in class II patients (47.5%), while survival was similarly low between class III and IV patients (22.5%). A statistically significant association was between class and survival (pv <0.001). CONCLUSION: Cesarean section delivery does not improve the perinatal outcomes of hydrops fetalis infants. Creating a validated tool for predicting the perinatal outcomes of infants with hydrops fetalis by mode of delivery is useful for assisting in decision-making and predicting perinatal outcomes.
Open AccessPrediction of Outcomes in Infants with Hydrops Fetalis by Mode of Delivery: A Retrospective Cohort from a Low-Resource Setting in Kenya
BACKGROUND: Hydrops fetalis is a condition associated with increased perinatal and neonatal mortality and morbidity. The overall survival rate of infants diagnosed with hydrops fetalis is currently estimated to be 27%, despite advanced intrauterine and neonatal care. Factors that contribute to poor perinatal and neonatal outcomes have been identified; however, little is known about the existing specific tool for predicting perinatal outcomes by mode of delivery. OBJECTIVE: This study aimed to determine whether cesarean section improves the perinatal outcomes of infants with hydrops fetalis in low-resource settings. STUDY DESIGN: This was a retrospective cohort study in which 102 medical records of pregnancies complicated by hydrops fetalis were retrieved. For all included women, transabdominal ultrasound was performed during pregnancy as part of the standard diagnostic modality for hydrops fetalis. The medical records of all pregnant women and their newborns were retrieved and reviewed to collect information related to the outcomes by mode of delivery, either cesarean section or vaginal delivery. The pregnant women were divided into the following 4 classes based on the severity of hydrops fetalis determined by obstetric ultrasound findings: class I (mild features of hydrops fetalis), II (moderate features of hydrops fetalis), III (moderately severe features of hydrops fetalis), and IV (severe features of hydrops fetalis). The significance of the obtained data was set at a two-tailed p<0.05. RESULTS: This cohort study estimated the proportion of hydrops fetalis to be 0.8%. Nonimmune hydrops fetalis was the common type, accounting for 75.6% of all cases. The 7-day survival rate was estimated to be 42.2%. There was no statistically significant association between the mode of delivery and perinatal survival (pv=0.84). Survival increased, especially in class II patients (47.5%), while survival was similarly low between class III and IV patients (22.5%). A statistically significant association was between class and survival (pv <0.001). CONCLUSION: Cesarean section delivery does not improve the perinatal outcomes of hydrops fetalis infants. Creating a validated tool for predicting the perinatal outcomes of infants with hydrops fetalis by mode of delivery is useful for assisting in decision-making and predicting perinatal outcomes.
- Open Access
- 16 January 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (1) , 98
Knowledge, Attitudes, and Subjective Norms Associated with COVID-19 Vaccination among Pregnant Women in Kenya: An Online Cross-Sectional Pilot Study Using WhatsApp
COVID-19 vaccination during pregnancy has been recommended, but the perceptions related to uptake remain unexplored. This pilot study aimed to explore how perceptions influence COVID-19 vaccine uptake among a sample of 115 pregnant women in Kenya, recruited via WhatsApp. Data were collected using an adapted online questionnaire between May and October 2022. Logistic analyses assessed the relationship between COVID-19 vaccination uptake and the Theory of Reasoned Action (TRA) constructs: attitudes and subjective norms. COVID-19 vaccination coverage was 73%, with vaccine hesitancy estimated at 41.4% among the unvaccinated group. Most participants had completed college education and had good knowledge of COVID-19 vaccines. There was no significant effect of enrollment in WhatsApp pregnancy groups on attitudes toward COVID-19 vaccination. Pregnant women were concerned about vaccine effectiveness (31.1%), and almost one-half (47.3%) were discouraged from receiving COVID-19 vaccines. Positive attitudes towards vaccination were associated with COVID-19 vaccination (aOR 2.81; 95% CI 1.12–7.04; p = 0.027), but no significant relationship was found between COVID-19 vaccination and strong subjective norms (influences to get COVID-19 vaccines). Our findings suggest that strategies to improve vaccination should consider targeting attitudes and proximal social networks (friends/family) to facilitate vaccination decision-making. WhatsApp can be used for research distribution and enhance the dissemination of accurate information.
- 16 January 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (1) , 98
Open AccessKnowledge, Attitudes, and Subjective Norms Associated with COVID-19 Vaccination among Pregnant Women in Kenya: An Online Cross-Sectional Pilot Study Using WhatsApp
COVID-19 vaccination during pregnancy has been recommended, but the perceptions related to uptake remain unexplored. This pilot study aimed to explore how perceptions influence COVID-19 vaccine uptake among a sample of 115 pregnant women in Kenya, recruited via WhatsApp. Data were collected using an adapted online questionnaire between May and October 2022. Logistic analyses assessed the relationship between COVID-19 vaccination uptake and the Theory of Reasoned Action (TRA) constructs: attitudes and subjective norms. COVID-19 vaccination coverage was 73%, with vaccine hesitancy estimated at 41.4% among the unvaccinated group. Most participants had completed college education and had good knowledge of COVID-19 vaccines. There was no significant effect of enrollment in WhatsApp pregnancy groups on attitudes toward COVID-19 vaccination. Pregnant women were concerned about vaccine effectiveness (31.1%), and almost one-half (47.3%) were discouraged from receiving COVID-19 vaccines. Positive attitudes towards vaccination were associated with COVID-19 vaccination (aOR 2.81; 95% CI 1.12–7.04; p = 0.027), but no significant relationship was found between COVID-19 vaccination and strong subjective norms (influences to get COVID-19 vaccines). Our findings suggest that strategies to improve vaccination should consider targeting attitudes and proximal social networks (friends/family) to facilitate vaccination decision-making. WhatsApp can be used for research distribution and enhance the dissemination of accurate information.
- Open Access
- 16 December 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (1) , ofac662
Human Immunodeficiency Virus Type 1 RNA Genital Tract Shedding After Cryotherapy for Cervical Intraepithelial Neoplasia in Western Kenya
This prospective study of 39 women living with human immunodeficiency virus (HIV) on antiretroviral therapy in Western Kenya aimed to quantify genital tract HIV-1 RNA (GT-HIV RNA) shedding before and after cryotherapy for cervical intraepithelial neoplasia. Most GT-HIV RNA shedding was detected precryotherapy, suggesting that cryotherapy was not the primary cause of shedding.
- 16 December 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (1) , ofac662
Open AccessHuman Immunodeficiency Virus Type 1 RNA Genital Tract Shedding After Cryotherapy for Cervical Intraepithelial Neoplasia in Western Kenya
This prospective study of 39 women living with human immunodeficiency virus (HIV) on antiretroviral therapy in Western Kenya aimed to quantify genital tract HIV-1 RNA (GT-HIV RNA) shedding before and after cryotherapy for cervical intraepithelial neoplasia. Most GT-HIV RNA shedding was detected precryotherapy, suggesting that cryotherapy was not the primary cause of shedding.
- Open Access
- 16 November 2020
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 15 (1) , 1-12
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review
Background: Cervical cancer screening is slowly transitioning from Pappanicolaou cytologic screening to primary Visual Inspection with Acetic Acid (VIA) or HPV testing as an effort to enhance early detection and treatment. However, an effective triage tests needed to decide who among the VIA or HPV positive women should receive further diagnostic evaluation to avoid unnecessary colposcopy referrals is still lacking. Evidence from experimental studies have shown potential usefulness of Squamous Cell Carcinoma Antigen (SCC Ag), Macrophage Colony Stimulating Factor (M-CSF), Vascular Endothelial Growth Factor (VEGF), MicroRNA, p16INKa / ki-67, HPV E6/E7/mRNA, and DNA methylation biomarkers in detecting premalignant cervical neoplasia. Given the variation in performance, and scanty review studies in this field, this systematic review described the diagnostic performance of some selected assays to detect high-grade cervical intraepithelial neoplasia (CIN2+) with histology as gold standard. Methods: We systematically searched articles published in English between 2012 and 2020 using key words from PubMed/Medline and SCOPUS with two reviewers assessing study eligibility, and risk of bias. We performed a descriptive presentation of the performance of each of the selected assays for the detection of CIN2 + . Results: Out of 298 citations retrieved, 58 articles were included. Participants with cervical histology yielded CIN2+ proportion range of 13.7–88.4%. The diagnostic performance of the assays to detect CIN2+ was; 1) SCC-Ag: range sensitivity of 78.6–81.2%, specificity 74–100%. 2) M-CSF: sensitivity of 68–87.7%, specificity 64.7–94% 3) VEGF: sensitivity of 56–83.5%, specificity 74.6–96%. 4) MicroRNA: sensitivity of 52.9–67.3%, specificity 76.4–94.4%. 5) p16INKa / ki-67: sensitivity of 50–100%, specificity 39–90.4%. 6) HPV E6/E7/mRNA: sensitivity of 65–100%, specificity 42.7–90.2%, and 7) DNA methylation: sensitivity of 59.7–92.9%, specificity 67–98%. Conclusion: Overall, the reported test performance and the receiving operating characteristics curves implies that implementation of p16ink4a/ki-67 assay as a triage for HPV positive women to be used at one visit with subsequent cryotherapy treatment is feasible. For the rest of assays, more robust clinical translation studies with larger consecutive cohorts of women participants is recommended.
- 16 November 2020
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 15 (1) , 1-12
Open AccessNovel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review
Background: Cervical cancer screening is slowly transitioning from Pappanicolaou cytologic screening to primary Visual Inspection with Acetic Acid (VIA) or HPV testing as an effort to enhance early detection and treatment. However, an effective triage tests needed to decide who among the VIA or HPV positive women should receive further diagnostic evaluation to avoid unnecessary colposcopy referrals is still lacking. Evidence from experimental studies have shown potential usefulness of Squamous Cell Carcinoma Antigen (SCC Ag), Macrophage Colony Stimulating Factor (M-CSF), Vascular Endothelial Growth Factor (VEGF), MicroRNA, p16INKa / ki-67, HPV E6/E7/mRNA, and DNA methylation biomarkers in detecting premalignant cervical neoplasia. Given the variation in performance, and scanty review studies in this field, this systematic review described the diagnostic performance of some selected assays to detect high-grade cervical intraepithelial neoplasia (CIN2+) with histology as gold standard. Methods: We systematically searched articles published in English between 2012 and 2020 using key words from PubMed/Medline and SCOPUS with two reviewers assessing study eligibility, and risk of bias. We performed a descriptive presentation of the performance of each of the selected assays for the detection of CIN2 + . Results: Out of 298 citations retrieved, 58 articles were included. Participants with cervical histology yielded CIN2+ proportion range of 13.7–88.4%. The diagnostic performance of the assays to detect CIN2+ was; 1) SCC-Ag: range sensitivity of 78.6–81.2%, specificity 74–100%. 2) M-CSF: sensitivity of 68–87.7%, specificity 64.7–94% 3) VEGF: sensitivity of 56–83.5%, specificity 74.6–96%. 4) MicroRNA: sensitivity of 52.9–67.3%, specificity 76.4–94.4%. 5) p16INKa / ki-67: sensitivity of 50–100%, specificity 39–90.4%. 6) HPV E6/E7/mRNA: sensitivity of 65–100%, specificity 42.7–90.2%, and 7) DNA methylation: sensitivity of 59.7–92.9%, specificity 67–98%. Conclusion: Overall, the reported test performance and the receiving operating characteristics curves implies that implementation of p16ink4a/ki-67 assay as a triage for HPV positive women to be used at one visit with subsequent cryotherapy treatment is feasible. For the rest of assays, more robust clinical translation studies with larger consecutive cohorts of women participants is recommended.
- Open Access
- 30 January 2020
- Published by Heighten Science Publications Corporation in International Journal of Clinical Virology
- Vol. 4 (1) , 001-005
Low sensitivity of the careHPV™ Assay for detection of Oncogenic Human Papillomavirus in cervical samples from HIV-infected and HIV-uninfected Kenyan women
Background: Human papillomavirus (HPV) infection causes cervical cancer (CC), a common malignancy among Kenyan women. New CC screening methods rely on oncogenic HPV (“high-risk”, or HR-HPV) detection, but most have not been evaluated in swabs from Kenyan women. Methods: HPV typing was performed on 155 cervical swabs from Kenyan women using the Roche Linear Array® (LA) and careHPV™ (careHPV) assays. Detection of 14 oncogenic HPV types in careHPV assay was compared to LA results. Results: Compared to LA, sensitivity and specificity of careHPV assay was 53.0% and 80.9%, respectively. The sensitivity and specificity of careHPV in swabs from women with cervical dysplasia was 74.1% and 65.2%, respectively. The sensitivity and specificity of careHPV in swabs from HIV-infected women was 55.9% and of 96.4%, respectively. Overall agreements of careHPV assay with LA was substantial. Conclusion: The results for careHPV assay are promising for oncogenic HPV detection in Kenyan women. The low sensitivity of careHPV for detection of HR-HPV could limit it’s benefit as a screening tool. Thus, a full clinical validation study is highly desirable before the careHPV assay can be accepted for cervical cancer screening.
- 30 January 2020
- Published by Heighten Science Publications Corporation in International Journal of Clinical Virology
- Vol. 4 (1) , 001-005
Open AccessLow sensitivity of the careHPV™ Assay for detection of Oncogenic Human Papillomavirus in cervical samples from HIV-infected and HIV-uninfected Kenyan women
Background: Human papillomavirus (HPV) infection causes cervical cancer (CC), a common malignancy among Kenyan women. New CC screening methods rely on oncogenic HPV (“high-risk”, or HR-HPV) detection, but most have not been evaluated in swabs from Kenyan women. Methods: HPV typing was performed on 155 cervical swabs from Kenyan women using the Roche Linear Array® (LA) and careHPV™ (careHPV) assays. Detection of 14 oncogenic HPV types in careHPV assay was compared to LA results. Results: Compared to LA, sensitivity and specificity of careHPV assay was 53.0% and 80.9%, respectively. The sensitivity and specificity of careHPV in swabs from women with cervical dysplasia was 74.1% and 65.2%, respectively. The sensitivity and specificity of careHPV in swabs from HIV-infected women was 55.9% and of 96.4%, respectively. Overall agreements of careHPV assay with LA was substantial. Conclusion: The results for careHPV assay are promising for oncogenic HPV detection in Kenyan women. The low sensitivity of careHPV for detection of HR-HPV could limit it’s benefit as a screening tool. Thus, a full clinical validation study is highly desirable before the careHPV assay can be accepted for cervical cancer screening.
- 19 October 2019
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 148 (3) , 403-404
Radical hysterectomy for operable early cervical cancer in HIV‐positive and HIV‐negative women in western Kenya
- 19 October 2019
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 148 (3) , 403-404
Radical hysterectomy for operable early cervical cancer in HIV‐positive and HIV‐negative women in western Kenya
- 7 June 2019
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 17 (3) , 55
Subcutaneous Metastasis of Cancer of the Endometrium
- 7 June 2019
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 17 (3) , 55
Subcutaneous Metastasis of Cancer of the Endometrium
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e17015
Comparison of HPV detection in HIV-infected and HIV-uninfected Kenyan women with or without cervical dysplasia.
E17015 Background: Cervical cancer, a malignancy caused by human papillomavirus (HPV) infection, is the most common malignancy in women living in sub-Saharan African countries including Kenya. HIV co-infection accelerates the natural course of cervical cancer. To determine the specific HPV type distribution in HIV-infected women compared to HIV-uninfected women, with and without evidence of cervical dysplasia. Methods: Demographic information, behavioral data, and a cervical swab were collected from women 18 and 45 years of age, HIV-infected or HIV-uninfected, who presented for cervical cancer screening at Moi Referral and Teaching Hospital in Eldoret, Kenya. Women were triaged based on the presence or absence of cervical dysplasia. HPV testing was performed using the Roche Linear Array Assay. Results were compared between women with or without HIV co-infection and between those with or without cervical dysplasia, using Chi-square tests or Fisher’s exact tests. Results: 223 women had normal VIAs. All had HPV testing, 221 had valid results: 115 HIV-infected women (mean age 37 years) and 106 HIV-uninfected (mean age 33 years). 175 women had abnormal VIAs. 143 women had HPV testing performed, 140 had valid results: 70 HIV-infected women (mean age 38.5 years) and 70 HIV-uninfected (mean age 31.3 years). Greater than 90% of all HIV-infected women in both projects were receiving anti-retroviral therapy at enrollment. HPV of any type was detected in 48% of all women with normal VIA vs. 61% of women with abnormal VIA (P = 0.018). High risk (HR)-HPV was detected in 38% of all women with normal VIA vs. 51% of all women with abnormal VIA (P = 0.012). HIV-uninfected women with normal VIA had significantly lower detection of all HPV (P = 0.026), high risk-HPV (P = 0.018), IARC high risk-HPV (P = 0.047), A9 types (P = 0.050), and individual types HPV 16 (P = 0.0274), HPV 18 (P = 0.007), and HPV 51 (P = 0.009) than HIV-uninfected women with abnormal VIA. Among HIV-infected women, there was no difference in detection of any group of HPV types or individual types with respect to VIA results. Conclusions: HIV-uninfected women without cervical dysplasia had lower detection of oncogenic HPV than HIV-uninfected women with dysplasia. In contrast, HPV detection did not differ among HIV-infected women between those with or without cervical dysplasia. In addition, VIA appears to lack specificity for HPV-associated cervical dysplasia, as 39% of women with abnormal VIA examinations did not have any HPV detected, and 49% of women with abnormal VIA examinations did not have any HR-HPV detected.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e17015
Comparison of HPV detection in HIV-infected and HIV-uninfected Kenyan women with or without cervical dysplasia.
E17015 Background: Cervical cancer, a malignancy caused by human papillomavirus (HPV) infection, is the most common malignancy in women living in sub-Saharan African countries including Kenya. HIV co-infection accelerates the natural course of cervical cancer. To determine the specific HPV type distribution in HIV-infected women compared to HIV-uninfected women, with and without evidence of cervical dysplasia. Methods: Demographic information, behavioral data, and a cervical swab were collected from women 18 and 45 years of age, HIV-infected or HIV-uninfected, who presented for cervical cancer screening at Moi Referral and Teaching Hospital in Eldoret, Kenya. Women were triaged based on the presence or absence of cervical dysplasia. HPV testing was performed using the Roche Linear Array Assay. Results were compared between women with or without HIV co-infection and between those with or without cervical dysplasia, using Chi-square tests or Fisher’s exact tests. Results: 223 women had normal VIAs. All had HPV testing, 221 had valid results: 115 HIV-infected women (mean age 37 years) and 106 HIV-uninfected (mean age 33 years). 175 women had abnormal VIAs. 143 women had HPV testing performed, 140 had valid results: 70 HIV-infected women (mean age 38.5 years) and 70 HIV-uninfected (mean age 31.3 years). Greater than 90% of all HIV-infected women in both projects were receiving anti-retroviral therapy at enrollment. HPV of any type was detected in 48% of all women with normal VIA vs. 61% of women with abnormal VIA (P = 0.018). High risk (HR)-HPV was detected in 38% of all women with normal VIA vs. 51% of all women with abnormal VIA (P = 0.012). HIV-uninfected women with normal VIA had significantly lower detection of all HPV (P = 0.026), high risk-HPV (P = 0.018), IARC high risk-HPV (P = 0.047), A9 types (P = 0.050), and individual types HPV 16 (P = 0.0274), HPV 18 (P = 0.007), and HPV 51 (P = 0.009) than HIV-uninfected women with abnormal VIA. Among HIV-infected women, there was no difference in detection of any group of HPV types or individual types with respect to VIA results. Conclusions: HIV-uninfected women without cervical dysplasia had lower detection of oncogenic HPV than HIV-uninfected women with dysplasia. In contrast, HPV detection did not differ among HIV-infected women between those with or without cervical dysplasia. In addition, VIA appears to lack specificity for HPV-associated cervical dysplasia, as 39% of women with abnormal VIA examinations did not have any HPV detected, and 49% of women with abnormal VIA examinations did not have any HR-HPV detected.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , 5530
Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV.
5530 Background: Cervical cancer is the leading cause of cancer-related deaths among women living in Africa. Only a small proportion of HPV-infected women develop cervical cancer and other cofactors may increase a woman’s risk of developing cervical cancer. Aflatoxin, a potent carcinogen and immunosuppressive agent, is produced by fungi that contaminate corn and other staple foods in sub-Saharan Africa. Women who ingest aflatoxin may be more likely to have persistent infections with oncogenic HPV type. Methods: Demographics, behavioral data, plasma, and cervical swabs were collected from HIV-uninfected women 18 and 45 years of age who presented for cervical cancer screening at Moi Referral and Teaching Hospital (Eldoret, Kenya) and had normal VIA examination. HPV testing was performed on cervical swabs using the Roche Linear Array Assay. Aflatoxin-albumin adduct (AFB1-lys) was detected and quantified in plasma. The association of plasma AFB1-lys detection and concentration and the detection of HPV was examined. Results: Sufficient plasma was available from 88 HIV-uninfected women and was transported to the U.S. for aflatoxin testing. Valid HPV testing results were available for 86 of these women (mean age 34.0 years); 49 women (57.0%) had detectable AFB1-lys and 37 (43.0%) had no detection. Substantial variation existed in plasma AFB1-lys concentrations among the 49 women (range 0.02 to 0.21 pg/µL). Detection of AFB1-lys was not associated with age, and other behavioral factors such as number of lifetime partners, marital status and age at first sex. AFB1-lys detection was associated with detection of A9 HPV types (HPV 16, 31, 33, 35, 52, and 58) as a group in cervical swabs (p = 0.029) as well as A9 types excluding HPV 16 (p = 0.020), but not with individual A9 types, A7 HPV types (such as HPV 18), or low-risk HPV types. A concentration dependent association of AFB1-lys was seen with detection of A9 HPV types as a group (p = 0.009), non-HPV 16 A9 types (p = 0.005), and HPV 52 (p = 0.042), but not with the A7 HPV types. Conclusions: AFB1-lys was detected in 57% of HIV-uninfected Kenyan women without cervical dysplasia. AFB1-lys-positive women were more likely than AFB1-lys-negative women to have oncogenic HPV A9 types detected. Higher plasma AFB1-lys concentrations were associated with increased likelihood of oncogenic HPV A9 type detection. Further studies are needed to determine if chronic exposure to aflatoxin interacts with HPV infection (and possibly HIV co-infection) to modulate the risk of cervical cancer in women in Kenya and other developing countries.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , 5530
Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV.
5530 Background: Cervical cancer is the leading cause of cancer-related deaths among women living in Africa. Only a small proportion of HPV-infected women develop cervical cancer and other cofactors may increase a woman’s risk of developing cervical cancer. Aflatoxin, a potent carcinogen and immunosuppressive agent, is produced by fungi that contaminate corn and other staple foods in sub-Saharan Africa. Women who ingest aflatoxin may be more likely to have persistent infections with oncogenic HPV type. Methods: Demographics, behavioral data, plasma, and cervical swabs were collected from HIV-uninfected women 18 and 45 years of age who presented for cervical cancer screening at Moi Referral and Teaching Hospital (Eldoret, Kenya) and had normal VIA examination. HPV testing was performed on cervical swabs using the Roche Linear Array Assay. Aflatoxin-albumin adduct (AFB1-lys) was detected and quantified in plasma. The association of plasma AFB1-lys detection and concentration and the detection of HPV was examined. Results: Sufficient plasma was available from 88 HIV-uninfected women and was transported to the U.S. for aflatoxin testing. Valid HPV testing results were available for 86 of these women (mean age 34.0 years); 49 women (57.0%) had detectable AFB1-lys and 37 (43.0%) had no detection. Substantial variation existed in plasma AFB1-lys concentrations among the 49 women (range 0.02 to 0.21 pg/µL). Detection of AFB1-lys was not associated with age, and other behavioral factors such as number of lifetime partners, marital status and age at first sex. AFB1-lys detection was associated with detection of A9 HPV types (HPV 16, 31, 33, 35, 52, and 58) as a group in cervical swabs (p = 0.029) as well as A9 types excluding HPV 16 (p = 0.020), but not with individual A9 types, A7 HPV types (such as HPV 18), or low-risk HPV types. A concentration dependent association of AFB1-lys was seen with detection of A9 HPV types as a group (p = 0.009), non-HPV 16 A9 types (p = 0.005), and HPV 52 (p = 0.042), but not with the A7 HPV types. Conclusions: AFB1-lys was detected in 57% of HIV-uninfected Kenyan women without cervical dysplasia. AFB1-lys-positive women were more likely than AFB1-lys-negative women to have oncogenic HPV A9 types detected. Higher plasma AFB1-lys concentrations were associated with increased likelihood of oncogenic HPV A9 type detection. Further studies are needed to determine if chronic exposure to aflatoxin interacts with HPV infection (and possibly HIV co-infection) to modulate the risk of cervical cancer in women in Kenya and other developing countries.